Alkermes to Participate in Upcoming Investor Conferences
Alkermes to Participate in Upcoming Investor Conferences
The live webcasts may be accessed under the Investors tab on and will be archived for 14 days.DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences.
都柏林，2024年11月25日 /PRNewswire/ -- 阿尔凯默斯（纳斯达克：ALKS）今天宣布管理层将参加两场即将举行的投资者会议。
7th Annual Evercore ISI HealthCONx Conference
Date/Time: Tuesday, Dec. 3, 2024 at 10:25 a.m. ET (3:25 p.m. GMT)
第7届Evercore ISI HealthCONx会议
日期/时间：2024年12月3日，星期二，上午10:25 ET（下午3:25 GMT）
Piper Sandler 36th Annual Healthcare Conference
Date/Time: Wednesday, Dec. 4, 2024 at 4:00 p.m. ET (9:00 p.m. GMT)
派杰投资第36届医疗保健年会
日期/时间：2024年12月4日，星期三，下午4:00 ET（晚上9:00 GMT）
The live webcasts may be accessed under the Investors tab on and will be archived for 14 days.
直播网络广播可在投资者标签下访问，并将保存14天。
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at .
关于阿尔凯默斯公
阿尔凯默斯股份有限公司是一家专注于神经科学领域开发创新药物的全球生物制药公司。该公司拥有自主商业产品组合，用于治疗酒精依赖、阿片类药物依赖、精神分裂症和双相情感障碍，以及在研发中开发用于神经系统疾病的临床和临床前候选药物管线，包括睡病和特发性睡眠过度嗜眠症。总部设在爱尔兰的阿尔凯默斯公司还在马萨诸塞州设有公司办公室和研发中心，在俄亥俄州设有制造设施。更多信息，请访问阿尔凯默斯公司的网站。
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
阿尔凯默斯联系人：
杰米·康斯坦丁
投资者关系
+1 781 873 2402
SOURCE Alkermes plc
资料来源：阿尔凯默斯。
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新闻在PRNEWSWIRE.COM上特色呈现吗？
